Lamivudine induced stable reversal in HBV liver cirrhosis Child C: a case report.
A 40-year-old viremic woman with HBV related liver cirrhosis (Child-Plugh - C) received 100 mg lamivudine daily for 24 months. Initially the patient was with hepato-splenomegaly, marked ascites and mild jaundice. There were no signs of portal encephalopaty and gastrointestinal haemorrhage. The baseline ALT was about 6 times above the upper limit of normal. Hypoalbuminemia of 29 g/l as well as hyperbilirubinemia of 40 mmol/L and decreased protrombin index of 47% was found. Serological tests showed positive serum HBsAg and anti-HBe antibodies. The patient was HBeAg negative, but with detectable serum HBV DNA (500 pg/mL) by dot-blot hybridization HDV, HCV and HIV co-infections were excluded. A marked improvement in liver function had been found at the end of the third month of therapy, with normalization of bilirubin and ALT activity. Serum albumin and protrombine index increased from 29 g/l to 36 g/l and from 47% to 92%, respectively. The patient was without ascites and Child-Plough score decreased from 10 to 5 points. Serum HBV DNA rapidly decreased at the end of first treatment month and was undetectable three months after the initiation of lamivudine therapy. We found two viremic episodes during the lamivudine treatment. However, Child-Pugh score did not increased and the patient remained with compensated liver disease and with lower ALT than baseline value. The main question is haw long such patients have to receive the lamivudine treatment.
Jelev
D
D
Clinic of Gastroenterology, St. Ivan Rilsky University Hospital, Medical University, Sofia, Bulgaria.
Krastev
Z
Z
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications*; D006801:Humans; D006932:Hyperbilirubinemia / Q000097:blood; D019259:Lamivudine / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology; D011517:Prothrombin Time; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D012709:Serum Albumin / Q000032:analysis
D018894:Reverse Transcriptase Inhibitors; D012709:Serum Albumin; D019259:Lamivudine; D000410:Alanine Transaminase